Episode Details

Back to Episodes
Pharmaceutical Executive Daily: FDA Approves Subcutaneous Formulation of Leqembi Iqlik

Pharmaceutical Executive Daily: FDA Approves Subcutaneous Formulation of Leqembi Iqlik

Published 4 months ago
Description
In today's Pharmaceutical Executive Daily, AstraZeneca acquires global rights to Dizal Pharmaceutical's lung cancer drug Zegfrovy in a deal worth up to $1.5 billion, FDA approves a subcutaneous formulation of Leqembi for early Alzheimer's disease, and a pharmacy executive weighs in on the education gap facing patients starting GLP-1 therapies.
Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us